Results of Meeting
Released
Released
Announcement PDF
Results of 2026 Extraordinary General Meeting
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 29 May 2026: Alterity Therapeutics (ASX: ATH, NASDAQ:
ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying
treatments for neurodegenerative diseases, today announced that in accordance with ASX Listing rule 3.13.2 and
Section 251AA of the Corporations Act 2001 (Cth), the attached information is provided in relation to the
resolutions passed by the shareholders of Alterity Therapeutics Limited at its Extraordinary General Meeting held
on 29 May 2026.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for
people living with neurodegenerative diseases. The Company is focused on developing disease modifying
therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate
a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has
demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical
trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in
participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable
chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in
Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s
website at https://alteritytx.com.
Authorisation & Additional information
This announcement was authorised by the Board of Alterity Therapeutics Limited.
Contacts:
Investors:
Elyse Shapiro
ir@alteritytx.com
Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386
Media
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of
1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking
statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may,"
"evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of
identifying suchstatements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking
statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most
recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following:
statements relating to the Company's drug development program, including, but not limited to the initiation,
progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to,
ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties,
including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing,
development, testing, regulatory approval, production and marketing of the Company’s drug components,including,
but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected
adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited
to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection
for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s
patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to
us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-
looking statement, whether written or oral, that may be made from time to time, whether as a result of new
information, future developments or otherwise.
Disclosure of Proxy Votes
Alterity Therapeutics Limited
General Meeting
Friday, 29 May 2026
In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.
Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814
Proxy Votes
Poll Results (if
applicable)
Results
Resolution
Decided by
Show of
Hands (S) or
Poll (P)
Total Number of
Proxy Votes
exercisable by
proxies validly
appointed
FOR AGAINST ABSTAIN
PROXY'S
DISCRETION
FOR AGAINST ABSTAIN OUTCOME
1 ELECTION OF DIRECTOR – MR JULIAN BABARCZY P 3,595,476,356
3,107,696,597
86.43%
446,154,929
12.41%
1,845,314
41,624,830
1.16%
3,160,365,713
87.63%
446,154,929
12.37%
1,845,314 Carried
2 ELECTION OF DIRECTOR – MS ANN CUNNINGHAM P 3,595,463,756
3,569,356,223
99.27%
20,486,203
0.57%
1,857,914
5,621,330
0.16%
3,586,021,839
99.43%
20,486,203
0.57%
1,857,914 Carried
3 CONSOLIDATION OF CAPITAL P 3,589,130,356
3,502,140,174
97.58%
81,297,424
2.27%
8,191,314
5,692,758
0.16%
3,507,832,932
97.44%
92,341,710
2.56%
8,191,314 Carried
4 APPROVAL TO ISSUE OPTIONS TO DIRECTOR – MR
JULIAN BABARCZY
P 3,593,598,277
2,969,540,026
82.63%
553,365,493
15.40%
3,723,393
70,692,758
1.97%
3,040,232,784
84.60%
553,365,493
15.40%
14,767,679 Carried
5 APPROVAL TO ISSUE OPTIONS TO MONTOYA PTY
LTD ATF BUTTERCUP TRUST
P 3,593,010,877
3,379,430,045
94.06%
207,888,074
5.79%
4,310,793
5,692,758
0.16%
3,385,122,803
94.21%
207,888,074
5.79%
15,355,079 Carried
6 AMENDMENT TO CONSTITUTION P 3,590,419,791
3,369,030,153
93.83%
215,264,808
6.00%
6,901,879
6,124,830
0.17%
3,386,199,269
94.02%
215,264,808
5.98%
6,901,879 Carried
7 APPROVAL TO ISSUE SECURITIES UNDER AN
INCENTIVE PLAN
P 3,559,461,277
3,427,086,943
96.28%
126,749,504
3.56%
37,860,393
5,624,830
0.16%
3,443,756,059
96.45%
126,749,504
3.55%
37,860,393 Carried
Share your feedback
Discover